<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLUOXETINE HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(flu'ox-e-tine)<br/><span class="topboxtradename">Prozac, </span><span class="topboxtradename">Prozac Weekly, </span><span class="topboxtradename">Sarafem<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">selective serotonin reuptake inhibitor (ssri)</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg tablets; 10 mg, 20 mg capsules; 20 mg/5 mL solution; 90 mg sustained-release capsules (Prozac Weekly)</p>
<h1><a name="action">Actions</a></h1>
<p>Oral antidepressant chemically unrelated to tricyclic, tetracyclic, <small>MAOI</small>, or other available antidepressants. Antidepressant effect is presumed to be linked to its inhibition of CNS neuronal uptake
         of serotonin, a neurotransmitter. Known as a selective serotonin reuptake inhibitor (SSRI).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectiveness may take from several days to 5 wk to develop fully. Drug has antidepressant, antiobsessive-compulsive, and
         antibulimic actions.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Depression, geriatric depression, obsessive-compulsive disorder (OCD), bulimia nervosa, premenstrual dysphoric disorder.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Obesity.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to fluoxetine or other SSRI drugs; concurrent administration with <small>MAOI</small>s, or thioridazine; pregnancy (category C), children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic and renal impairment, renal failure, abrupt discontinuation, anorexia nervosa, mania, bleeding, lactation; hyponatremia,
         cardiac disease, dehydration, diabetes mellitus, patients with history of suicidal ideations; seizure disorders, ECT, hepatic
         disease. Older adults may require dose adjustments.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Depression, Obsessive-Compulsive Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg/d in a.m., may increase by 20 mg/d at weekly intervals (max: 80 mg/d); 20 mg/d in a.m.; when stable may switch to 90
               mg sustained-release capsule qwk (max: 90 mg/wk)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt; 7 y</i> 1020 mg/d in a.m. (max: 60 mg/d for OCD)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 10 mg/d<br/><br/><span class="indicationtitle">Premenstrual Dysphoric Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1020 mg q.d. (max: 60 mg/d)<br/><br/><span class="indicationtitle">Bulimia Nervosa</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give as a single dose in morning. Give in two divided doses; one in a.m. and one at noon to prevent insomnia, when more than
            20 mg/d prescribed.
         </li>
<li>Provide suicidal or potentially suicidal patient with small quantities of prescription medication.</li>
<li>Monitor for worsening of depression or expression of suicidal ideations.</li>
<li>Store at 15°25° C (59°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Headache, nervousness, anxiety, insomnia,</span> drowsiness, fatigue, tremor, dizziness. <span class="typehead"> CV:</span>  Palpitations, hot flushes, chest pain. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, diarrhea,</span> anorexia, dyspepsia, increased appetite, dry mouth. <span class="typehead">Skin:</span> Rash, pruritus, sweating, hypersensitivity reactions. <span class="typehead">Special Senses:</span> Blurred vision. <span class="typehead">Body as a Whole:</span> Myalgias, arthralgias, flu-like syndrome, hyponatremia. <span class="typehead">Urogenital:</span> Sexual dysfunction, menstrual irregularities. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Concurrent use of <b>tryptophan</b> may cause agitation, restlessness, and GI distress; <span class="classification">mao inhibitors</span>, <b>selegiline</b> may increase risk of severe hypertensive reaction and death; increases half-life of <b>diazepam;</b> may increase toxicity of <span class="classification">tricyclic antidepressants</span>; <span class="classification">amphetamines</span>, <b>cilostazol,</b>
<b>nefazodone,</b>
<b>pentazocine,</b>
<b>propafenone,</b>
<b>sibutramine,</b>
<b>tramadol,</b>
<b>venlafaxine</b> may increase risk of serotonin syndrome; may inhibit metabolism of <b>carbamazepine,</b>
<b>phenytoin,</b>
<b>ritonavir;</b> increased ergotamine toxicity with <b>dihydroergotamine,</b>
<b>ergotamine.</b>
<span class="typehead">Herbal:</span>
<b>St. John's wort</b> may cause serotonin syndrome. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 6080% absorbed from GI tract. <span class="typehead">Onset:</span> 13 wk. <span class="typehead">Peak:</span> 48 h. <span class="typehead">Distribution:</span> Widely distributed, including CNS. <span class="typehead">Metabolism:</span> Metabolized in liver to active metabolite, norfluoxetine. <span class="typehead">Elimination:</span> &gt;80% excreted in urine; 12% in feces. <span class="typehead">Half-Life:</span> Fluoxetine 23 d, norfluoxetine 79 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Use with caution in the older adult patient or patient with impaired renal or hepatic function (may need lower dose).</li>
<li>Use with caution in anorexic patient, since weight loss is a possible side effect.</li>
<li>Monitor for S&amp;S of anaphylactoid reaction (see Appendix F).</li>
<li>Lab tests: Periodic serum electrolytes; monitor closely plasma glucose in diabetes.</li>
<li>Monitor serum sodium level for development of hyponatremia, especially in patients who are taking diuretics or are otherwise
            hypovolemic.
         </li>
<li>Monitor diabetics for loss of glycemic control; hypoglycemia has occurred during initiation of therapy, and hyperglycemia
            during drug withdrawal.
         </li>
<li>Monitor for S&amp;S of improved affect. Requires approximately 23 wk for therapeutic effects to be felt.</li>
<li>Weigh weekly to monitor weight loss, particularly in the older adult or nutritionally compromised patient. Report significant
            weight loss to physician.
         </li>
<li>Observe for and promptly report rash or urticaria and S&amp;S of fever, leukocytosis, arthralgias, carpal tunnel syndrome, edema,
            respiratory distress, and proteinuria. Drug may have to be discontinued or adjunctive therapy instituted with steroids or
            antihistamines.
         </li>
<li>Observe for dizziness and drowsiness and employ safety measures (up with assistance, side rails, etc.) as indicated.</li>
<li>Monitor for and report increased anxiety, nervousness, or insomnia; may need modification of drug dose.</li>
<li>Monitor for seizures in patients with a history of seizures. Use appropriate safety precautions.</li>
<li>Supervise patients closely who are high suicide risks; especially during initial therapy.</li>
<li>Monitor patients with hepatic or renal impairment carefully for S&amp;S of toxicity (e.g., agitation, restlessness, nausea, vomiting,
            seizures).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician of intent to become pregnant.</li>
<li>Notify physician of any rash; possible sign of a serious group of adverse effects.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known; especially if dizziness noted.</li>
<li>Monitor blood glucose for loss of glycemic control if diabetic.</li>
<li>
            							Note: Drug may increase seizure activity in those with history of seizure.
            						
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>